DIA (Drug Information Association) China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
Dong previously held executive positions as CEO for Lilly China Research and Development Co., a subsidiary of Eli Lilly and Company, and was president and CEO of IMPACT Therapeutics, Inc. He has been employed by Roche in China and the U.S., and by other Chinese and international companies, working in R&D, sales and marketing, business development and executive management.
Dong is a full professor at Nanjing University of Technology, and was named a “Leading Talent in Creativity, Innovation and Entrepreneurship” by the Nanjing New & High Technology Industry Development Zone. He holds an MBA from the China Europe International Business School and a doctorate in chemistry from the University of Washington.
This appointment was prompted by the retirement of Jane Cai, PhD, from the role of DIA China regional director. Under her direction, DIA China was established in 2011 as a legal entity, DIA Beijing Healthcare Information Consulting Ltd. Also, participation of attendees and exhibitors in DIA China Annual Meeting participation doubled, as did membership numbers.
Read the full release here.